NovaBridge Biosciences (NBP) investor relations material

Company overview and strategy

• Operates a global biotech platform with a portfolio of first- and best-in-class programs in oncology and ophthalmology.

• Evolved from a China-focused biotech to a global platform, now pursuing asset-based and platform-based business models.

• Focuses on accelerated development and value creation through unique clinical strategies and strong business development expertise.

• Maintains a healthy cash runway of $210.8M, supporting operations through 2028.

• Led by a seasoned management team with deep industry and regional experience.

Pipeline and clinical programs

• Four clinical-stage assets: Givastomig (CLDN18.2 x 4-1BB bsAb), VIS-101 (VEGF-A x ANG-2 bsAb), Ragistomig (PD-L1 x 4-1BB bsAb), and Uliledlimab (CD73 mAb).

• Givastomig shows robust and durable responses in 1L gastric cancer, with broad coverage across CLDN18.2 expression levels.

• VIS-101 demonstrates rapid, robust, and durable responses in retinal vascular diseases, with best-in-class durability potential.

• Ragistomig and Uliledlimab offer differentiated mechanisms and promising efficacy in solid tumors and NSCLC, respectively.

Givastomig clinical data and market opportunity

• Phase 1b data show ORR of 75% and mPFS of 16.9 months in 1L gastric cancer, outperforming current standards.

• Efficacy observed across all CLDN18.2 and PD-L1 levels, with manageable safety profile and low incidence of severe adverse events.

• Addresses a significant unmet need in gastric cancer, with potential to reach >70% of the CLDN18.2 market.

• Estimated global peak sales for Givastomig in metastatic gastric cancer could reach ~$12B.